AOL Money & Finance

Celgene acquiring Pharmion -- a smart move

Posted Nov 19th 2007 9:08AM by Zack MillerZack Miller RSS Feed

More

Celgene (NASDAQ: CELG), a quickly-growing biotech firm focused on technologies to treat cancer and immune-inflammatory-related diseases, announced today that the company is acquiring Pharmion Corp. (NASDAQ: PHRM) for a tad under $3 billion. Celgene markets proprietary thalidomide-based drugs for blood cancers. The acquisition of Pharmion gives Celgene a leukemia treatment that helped patients live longer in a study.

Pharmion holders will get $72 a share, 46% higher than Pharmion's most recent closing stock price of $49.28 on November 16.

This deal is being warmly received on Wall Street. While expensive, "there are few deals that make as much business sense and add as many operating synergies in the biotechnology space," according to a report from Bank of America. "With the acquisition, Celgene is increasing the depth of its pipeline which we believe was required for the next leg of growth. Celgene is acquiring a pipeline including Vidaza, a potential best in class therapy for Myelodysplastic syndromes (MDS)."

Celgene is a quickly-growing biotechnology firm that is now shoring up its pipeline with a new therapy with lots of potential. Mr. Mad Money himself has publicly supported Celgene. You can see what BloggingStocks had to say about Cramer's interview with Celgene COO back earlier this year.

Tags: biotech, celg, celgene, inthenews, pharma, pharmion, phrm

Symbol Lookup
IndexesChangePrice
DJIA+17.4610,023.42
NASDAQ+7.122,112.44
S&P 500+2.671,069.30

Last updated: November 09, 2009: 04:47 AM

BloggingStocks Exclusives

Hot Stocks

DailyFinance Headlines

Latest from BloggingBuyouts

TheFlyOnTheWall.com Headlines

    BioHealth Investor Headlines

    WalletPop Headlines

    My Portfolios

    Track your stocks here!

    Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

    • My Portfolio
    • Create a New Portfolio

    BloggingStocks Partners

    More from AOL Money & Finance

    WalletPop Headlines